Abiopharma

🔍 Torley Helen (Director)

Company: HALOZYME THERAPEUTICS, INC. (HALO)

Report Date: 2025-12-09

Detailed Transactions and Holdings:

• Acquired 165,522 shares of Performance Stock Units (Derivative)
  Date: 2025-12-09 | Code: A | equity_swap_involved: 0 | shares_owned_after: 165,522.00 | transaction_form_type: 4 | Footnotes: F1, F1, F1

Footnotes:

• F1: Represents the grant of performance-based vesting Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of HALO common stock. The target number of Restricted Stock Units subject to the award is indicated. Up to two hundred percent (200%) of the target Restricted Stock Units could vest if the average closing price of HALO common stock over a period of 20 consecutive trading days during a four-year performance period following the grant of the award equals or exceeds certain price levels specified in the award (with 50% of target number of units vesting at $115 and an additional 50% of the target number of units vesting at each of $130, $145 and $170) and, in each case, only if the Reporting Person remains employed with the Registrant through the end of the performance period (subject to certain exceptions provided in the applicable award agreement).